Every year on October 25, hematologists, cancer researchers, patient advocacy coalitions, and survivors observe MDS World Awareness Day. Organized internationally by the MDS Foundation, this global clinical campaign educates healthcare providers and the public on Myelodysplastic Syndromes (MDS), often described as bone marrow failure disorders.
Understanding the Pathophysiology of MDS
In patients with Myelodysplastic Syndromes, genetic mutations within hematopoietic stem cells in the bone marrow prevent blood precursor cells from maturing into healthy erythrocytes (red blood cells), leukocytes (white blood cells), or thrombocytes (platelets). This leads to severe chronic anaemia, heightened vulnerability to life-threatening infections, and excessive bruising. Approximately one-third of MDS cases progress to Acute Myeloid Leukemia (AML).
The Lifesaving Power of Allogeneic Stem Cell Transplants
While targeted hypomethylating therapies and growth factor injections help manage symptoms, the only potential cure for high-risk MDS remains an allogeneic hematopoietic stem cell (bone marrow) transplant. On October 25, organizations urge healthy individuals aged 18 to 40 to join national bone marrow donor registries through simple cheek-swab kits, providing hope to patients awaiting matched donors worldwide.
